In MDCK multicycle growth assays, Nanchangmycin at 1 μM produced an approximately 100- fold decrease in viral production compared with media alone. In A549 cells, Nanchangmycin inhibited rubella virus infection with a half-maximal inhibitory concentration of 0.03 µM, normalized to DMSO vehicle control. In pretreated U2OS cells, Nanchangmycin blocked transferrin-conjugated bead internalization equivalently to dynasore. In MDCK cells exposed to oseltamivir-resistant influenza A virus, survival with Nanchangmycin reached 50% in comparison with oseltamivir carboxylate or DMSO. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Reduced viral production in MDCK cells
Cell-based study · MDCK cells [1]
In MDCK cells, Nanchangmycin at 1 μM produced an approximately 100- fold decrease in viral production compared with media alone in multicycle growth assays.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 6–72 h
- Method
- with media alone or with the nanchangmycin
- Co-treatment
- Other interventions in this design: H1N1 MOI of 0.01. Compound effect isolated by the comparison: media alone or with the nanchangmycin.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Nanchangmycin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Viral titer reduction assay (S21, S22, S23); Results > Screening for inhibitors of IAV infection via the HA assay (S90)
infectious viral particles were titered via TCID 50 assay: infectious viral particles were titered via TCID 50 assay; comparator: media alone — Materials and Methods > Viral titer reduction assay (S23); Results > Screening for inhibitors of IAV infection via the HA assay (S90)
Inhibition of rubella virus infection in A549 cells
Cell-based study · A549 cells [2]
In A549 cells treated with Nanchangmycin, rubella virus infection was inhibited with a half-maximal inhibitory concentration of 0.03 µM, normalized to the DMSO vehicle control.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 hpi
- Method
- treated with indicated concentrations of nanchangmycin
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: rubella RA27/3 virus MOI = 0.2. Compound effect isolated by the comparison: normalized to vehicle control (DMSO).
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: Nanchangmycin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > High-throughput screen for antivirals against rubella virus (S6); Materials and methods > High-throughput screen (S88, S98); Materials and methods > Dose–responses (S101, S104); Fig. 1. legend (S132, S133, S134)
percent infection: percent infection; comparator: vehicle control (DMSO) — Results > High-throughput screen for antivirals against rubella virus (S6); Fig. 1. legend (S134)
Blockade of transferrin-conjugated bead uptake in U2OS cells
Cell-based study · U2OS cells [3]
U2OS cells were pretreated with Nanchangmycin before exposure to transferrin-conjugated beads. Nanchangmycin blocked bead internalization equivalently to dynasore.
Literature-Reported Treatment Conditions
- Exposure duration
- pretreated with the indicated drug for 45 min and subsequently treated with transferrin-conjugated beads for 45 min
- Method
- pretreated
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: Nanchangmycin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Flaviviral Uptake and Large-Cargo Internalization Are Dependent upon Microtubules. (S63); Fig. 4. legend (S113, S116)
Quantification of transferrin-conjugated bead uptake (Mander’s colocalization analysis): Quantification of transferrin-conjugated bead uptake (Mander’s colocalization analysis); comparator: dynasore, an inhibitor of dynamin — Results > Flaviviral Uptake and Large-Cargo Internalization Are Dependent upon Microtubules. (S63); Fig. 4. legend (S116)
Cell survival during oseltamivir-resistant influenza A virus exposure
Cell-based study · MDCK cells [1]
In MDCK cells exposed to oseltamivir-resistant influenza A virus, survival with Nanchangmycin reached 50% in comparison with oseltamivir carboxylate or DMSO.
Literature-Reported Treatment Conditions
- Method
- in the presence of nanchangmycin
- Co-treatment
- Other interventions in this design: Influenza A virus (oseltamivir-resistant) MOI of 1. Compound effect isolated by the comparison: Compared with oseltamivir carboxylate or DMSO.
- Reported limits
- Not stated in the sentences used: dose, schedule, vehicle.
Methods and source locations
Compound reported in the paper: Nanchangmycin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Oseltamivir-resistant influenza virus sensitivity assay (S41); Results > Oseltamivir-resistant influenza virus is sensitive to nanchangmycin, which has broad-spectrum antiviral activity (S143)
survival rate of MDCK cells: survival rate of MDCK cells; comparator: oseltamivir carboxylate or DMSO — Results > Oseltamivir-resistant influenza virus is sensitive to nanchangmycin, which has broad-spectrum antiviral activity (S143)